Compare Stocks → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADRONASDAQ:ETONNASDAQ:GTXINASDAQ:MBIONASDAQ:TOCA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADROAduro Biotech$10.93$4.51▼$20.20$236.61M0.4162,237 shs171,500 shsETONEton Pharmaceuticals$3.19+4.2%$3.98$2.42▼$5.81$81.95M1.1768,842 shs33,789 shsGTXIGTX$8.86+3.0%$4.77$0.74▼$25.60$213.08M2.22390,540 shs4,539 shsMBIOMustang Bio$0.34-8.1%$1.02$0.33▼$8.17$3.55M1.58177,262 shs129,383 shsTOCATocagen$0.73-6.4%$32.24$0.42▼$6.77$17.56M0.011.47 million shs8,346 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADROAduro Biotech0.00%0.00%0.00%0.00%0.00%ETONEton Pharmaceuticals-2.55%-11.05%-13.56%-26.09%-16.16%GTXIGTX-3.91%-3.80%+9.14%+10.26%+2,412.42%MBIOMustang Bio-3.39%-32.20%-64.50%-72.52%-90.82%TOCATocagen+5.41%+8.33%+18.18%+12.13%-26.42%Secret Bull Market Starts in This Unusual Sector (Ad)"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. Click for my No. 1 investment, all free of charge, click here. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADROAduro BiotechN/AN/AN/AN/AN/AN/AN/AN/AETONEton Pharmaceuticals2.3496 of 5 stars3.55.00.00.02.70.80.0GTXIGTXN/AN/AN/AN/AN/AN/AN/AN/AMBIOMustang Bio1.6505 of 5 stars3.55.00.00.01.60.00.0TOCATocagenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADROAduro BiotechN/AN/AN/AN/AETONEton Pharmaceuticals3.00Buy$10.00213.48% UpsideGTXIGTXN/AN/AN/AN/AMBIOMustang Bio3.00Buy$17.254,949.77% UpsideTOCATocagenN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADROAduro Biotech$17.26M0.00N/AN/A$4.07 per share0.00ETONEton Pharmaceuticals$31.64M2.59$0.00 per share982.54$0.60 per share5.32GTXIGTXN/AN/AN/AN/A$1.09 per shareN/AMBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/ATOCATocagen$40K438.91N/AN/A$0.45 per share1.63Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADROAduro Biotech-$82.37M-$5.15N/AN/AN/A-230.92%-101.73%-22.35%N/AETONEton Pharmaceuticals-$940K-$0.03N/A∞N/A-2.96%-6.21%-3.17%5/9/2024 (Estimated)GTXIGTX-$38.42M-$1.65N/AN/AN/AN/A-104.19%-86.42%N/AMBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)TOCATocagen-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/ALatest TOCA, ETON, GTXI, MBIO, and ADRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023ETONEton Pharmaceuticals-$0.04-$0.09-$0.05-$0.09$7.70 million$7.31 million 3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADROAduro BiotechN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AGTXIGTXN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADROAduro BiotechN/A8.918.91ETONEton PharmaceuticalsN/A1.651.60GTXIGTXN/A12.3912.39MBIOMustang BioN/A0.740.74TOCATocagen1.881.151.15OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADROAduro Biotech49.93%ETONEton Pharmaceuticals27.86%GTXIGTX9.50%MBIOMustang Bio9.95%TOCATocagen21.42%Insider OwnershipCompanyInsider OwnershipADROAduro Biotech5.90%ETONEton Pharmaceuticals13.16%GTXIGTX40.90%MBIOMustang Bio2.10%TOCATocagen10.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADROAduro Biotech15216.21 millionN/AOptionableETONEton Pharmaceuticals3025.69 million22.31 millionOptionableGTXIGTX2124.05 millionN/ANot OptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionableTOCATocagen7723.92 millionN/ANot OptionableTOCA, ETON, GTXI, MBIO, and ADRO HeadlinesSourceHeadlineGlioblastoma Treatment Market Expected to Reach USD 10.3 Billion by 2032 | Marketresearch.bizpharmiweb.com - March 25 at 4:25 AMONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Gliomaascopubs.org - February 12 at 6:14 PMMiami Cancer Institute publication analyzes role of tissue-agnostic therapies for the treatment of primary brain tumorseurekalert.org - January 20 at 12:14 AMForte Biosciences: Changes In Registrant S Certifying Accountantcbonds.com - December 12 at 8:27 AMRiskOn International And 3 Other Stocks Under $2 Insiders Are Buyingmarkets.businessinsider.com - December 11 at 9:20 AMPrecision and personalized medicine: the leading companies in personalized cancer vaccines revealedpharmaceutical-technology.com - November 6 at 9:33 AMProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointmentfinance.yahoo.com - November 2 at 10:33 AMFDA Clears Phase II Trial of Denovo Biopharma Gene Therapy in Glioma Patientsprecisionmedicineonline.com - July 26 at 11:09 PMGene Therapy Market Report 2023 Provides SWOT Analysis ... - openPRnews.google.com - May 12 at 8:33 AMForm DEF 14A CTI BIOPHARMA CORP For: Jun 21 - StreetInsider.comnews.google.com - April 29 at 12:45 AMGenomic and transcriptomic analysis of checkpoint blockade ... - Nature.comnews.google.com - April 6 at 8:25 PMBelzutifan plus cabozantinib for patients with advanced clear cell ... - The Lancetnews.google.com - March 31 at 11:10 PMCurrent drug development and trial designs in neuro-oncology ... - The Lancetnews.google.com - March 28 at 12:07 AMCompanion Diagnostics Market is set to experience a significant ... - Digital Journalnews.google.com - March 27 at 8:37 AMOligodendroglioma Pipeline Drugs and Companies Insight Report ... - Digital Journalnews.google.com - March 14 at 4:44 PMAnaplastic Astrocytoma Drug Market| Global Industry Analysis ... - Digital Journalnews.google.com - March 8 at 10:39 AMAnaplastic Oligoastrocytoma Market Focus On Estimation, Research ... - Taiwan Newsnews.google.com - March 2 at 1:05 PMAnaplastic Oligoastrocytoma Market Industry Analysis, Estimates Size and Projections by 2029marketwatch.com - February 28 at 3:22 AMCompanion Diagnostics Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029marketwatch.com - February 27 at 9:31 AMAn echo through brain cancer’s empty pipelinepharmaphorum.com - February 7 at 7:04 PMCompanion Diagnostics Market Size, Share, Growth Statistics By ... - Digital Journalnews.google.com - February 3 at 6:12 AMCardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer - Yahoo Financenews.google.com - February 2 at 1:10 PMCardiff Oncology Announces the Appointment of Fairooz Kabbinavar ... - PR Newswirenews.google.com - February 2 at 8:09 AMHuman Resource Management Market Booming Worldwide With ... - Rejoice Magazinenews.google.com - January 27 at 11:36 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAduro BiotechNASDAQ:ADROChinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.Eton PharmaceuticalsNASDAQ:ETONEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.GTXNASDAQ:GTXIGTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.TocagenNASDAQ:TOCATocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.